Proliferative activity in Barrett's esophagus before and after antireflux surgery

Annals of Surgery

Volumn 234, Issue 2, 2001, Pages 172-180

  Chen, Long Qi ^a   Hu, Chun Yan ^a   Gaboury, Louis ^a   Pera, Manuel ^b   Ferraro, Pasquale ^a   Duranceau, Andŕ C ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; CELL PROLIFERATION; DYSPLASIA; ESOPHAGUS MUCOSA; FEMALE; GASTROPLASTY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MANOMETRY; PH; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK FACTOR; SURGICAL APPROACH;

EID: 0034903804     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200108000-00006     Document Type: Article

References (48)

1. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett
2. Barrett's esophagus: Its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux
3. Barrett's esophagus. Prevalence and incidence of adenocarcinoma
4. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological study
5. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus
6. Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy
7. Functional foregut abnormalities in Barrett's esophagus
8. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized
9. Results of the Collis-Nissen gastroplasty in patients with Barrett's esophagus
10. Alkaline gastroesophageal reflux: Implication in the development of complications in Barrett's columnar-lined lower esophagus
11. Bile reflux in benign and malignant Barrett's esophagus: Effect of medical acid suppression and nissen fundoplication
12. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety
13. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
14. Normal patterns of acid exposure at the gastric cardia: A functional midpoint between the esophagus and stomach
15. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus
16. Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus
17. Barrett's oesophagus and proton pump inhibitors: A pathological perspective
18. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model
19. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression
20. Regression of columnarlined (Barrett's) oesophagus with omeprazole 40 mg daily: Results of 5 years of continuous therapy
21. Role of antireflex surgery against dysplasia in Barrett's esophagus
22. Conservative treatment versus antireflux surgery in Barrett's oesophagus: Long-term results of a prospective study
23. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus
24. The application of immunohistochemistry in assessment of cellular proliferation
25. Comparison of labelling by bromodeoxyuridine, MIB-1, and proliferating cell nuclear antigen in gastric mucosal biopsy specimens
26. Cell kinetic study of human carcinomas using bromodeoxyuridine
27. A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa
28. Abnormal expression of growth regulatory factors in Barrett's oesophagus
29. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus
30. Maintenance therapy: Is there still a place for antireflux surgery?
31. Early detection of neoplasia of the esophagus and gastroesophageal junction
32. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
33. Barrett's esophagus: Cell cycle abnormalities in advancing stages of neoplastic progression
34. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization
35. Barrett's esophagus: The biology of neoplastic progression
36. Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression
37. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma
38. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: A comparative study
39. Long-term continuous omeprazole treatment of patients with Barrett's oesophagus
40. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double-blind study
41. Histological and anatomic changes in Barrett's esophagus after antireflux surgery
42. Squamous islands in Barrett's esophagus: What lies underneath?
43. Clinical trial of omeprazole in patients with Barrett's oesophagus
44. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus
45. Increased expression of the cyclin D1 gene in Barrett's esophagus
46. Secretory function of Barrett's epithelium
47. Gastroesophageal reflux in achalasia. When is reflux really reflux?
48. Endoscopic fluorescence detection of dysplasia in patients with Barrett's esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization